FDA Brief

Warning letters Drugs

FDA warning letter to

Hangzhou Glamcos Biotech Co., Ltd.

High riskIssued Oct 7, 2024Posted Mar 25, 2025Center for Drug Evaluation and Research (CDER)

Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.

What happened

FDA reviewed records and other information the company submitted after FDA’s March 4, 2024 request under section 704(a)(4) of the FD&C Act; this was a records review, not an inspection. FDA found significant CGMP violations, including no adequate finished-product release testing, no adequate identity testing of high-risk components such as glycerin and propylene glycol, inadequate stability testing, and incomplete batch records. FDA also found that “disinpro multi-purpose ANTIBACTERIAL WIPES” was an unapproved new drug and that both wipes products were misbranded, and it noted a discrepancy in the company’s statements about U.S. drug shipments.

What FDA found

  1. The firm did not test each finished batch for identity and strength of active ingredients before release.

    21 CFR 211.165(a)
  2. The firm did not adequately test incoming glycerin and propylene glycol for identity, including DEG/EG limits, or verify supplier test results.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The firm’s stability program did not test active ingredients or show products stay acceptable through their expiry dates.

    21 CFR 211.166(a)
  4. The firm’s batch production records did not document each significant manufacturing step.

    21 CFR 211.188
  5. The firm marketed “disinpro multi-purpose ANTIBACTERIAL WIPES” as an unapproved new drug, with benzalkonium chloride at 0.2% instead of the permitted 0.1% to 0.13%.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a), 331(d)
  6. Both wipes product labels lacked the required complete warning “If swallowed, get medical help or contact a Poison Control Center right away,” and “disinpro” did not meet 505G marketing requirements.

    FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2); section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA asks the firm to respond in writing within 15 working days with what it has done to correct violations and prevent recurrence, and to clarify whether it will continue making drugs for the U.S. market. FDA also recommends a qualified CGMP consultant and a six-system audit, and says the firm must notify FDA before resuming drug manufacturing.

Who should pay attention

  • brands and distributors selling imported OTC antibacterial wipes
  • companies buying OTC drugs from Chinese contract manufacturers
  • buyers and suppliers relying on glycerin or propylene glycol identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk